MDxHealth signs biomarker deal for Pfizer's PARP inhibitor
This article was originally published in Scrip
Executive Summary
The molecular diagnostics specialist MDxHealth is to help Pfizer identify and develop biomarkers to predict patient responses to its investigational PARP inhibitor, PF-01367338.